A carregar...
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
PURPOSE: Regorafenib is a standard-care option for treatment-refractory metastatic colorectal cancer that increases median overall survival by 6 weeks compared with placebo. Given this small incremental clinical benefit, we evaluated the cost-effectiveness of regorafenib in the third-line setting fo...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4737857/ https://ncbi.nlm.nih.gov/pubmed/26304904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.9569 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|